Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Paola Neri, MD, PhD

Associate Professor of Medicine
University of Calgary
Calgary, Alberta, Canada

Disclosures

Paola Neri, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Bristol Myers Squibb Company; Janssen Pharmaceuticals; Pfizer, Inc.; Sanofi

Noopur Raje, MD

Director
Center for Myeloma
Massachusetts General Hospital
Boston, Massachusetts, United States

Disclosures

Noopur Raje, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Amgen, Inc.; Bristol Myers Squibb Company; Caribou Bioscience; Immuneel Therapeutics; Janssen Pharmaceuticals; Pfizer, Inc.; Sanofi; Takeda Pharmaceuticals North America, Inc.
Research funding from: bluebird bio, Inc.

Rakesh Popat, MD

University College London Hospitals
NHS Foundation Trust
London, United Kingdom

Disclosures

Rakesh Popat, MD, has the following relevant financial relationships:
Consultant or advisor for: GlaxoSmithKline; Janssen
Speaker or member of speakers bureau for: AbbVie, Inc.; Bristol Myers Squibb Company; GlaxoSmithKline; Janssen Pharmaceuticals; Pfizer, Inc.
Research funding from: GlaxoSmithKline

Krina Patel, MD, MSc

Associate Professor
Center Medical Director
Department of Lymphoma/Myeloma
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas, United States

Disclosures

Krina Patel, MD, MSc, has the following relevant financial relationships:
Consultant or advisor for: Arcellx; Bristol Myers Squibb Company; Celgene Corporation; Cellectis; Janssen Pharmaceuticals; Karyopharm; Oncopeptides; Pfizer, Inc.
Contracted researcher for: Allogene Therapeutics; Bristol Myers Squibb Company; Celgene Corporation; Cellectis; Nektar Therapeutics; Precision Biosciences; Takeda Pharmaceuticals North America, Inc.

Editors

Sanneke Koekkoek

Medical Education Director, Medscape, LLC

Disclosures

Sanneke Koekkoek has no relevant financial relationships.

Eloise Ballard, PhD

Scientific Content Manager, Medscape, LLC

Disclosures

Eloise Ballard, PhD, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME

Managing Relapsed/Refractory Multiple Myeloma: The Ever-Expanding Role of B-Cell Maturation Antigen as a Molecular Target

Authors: Paola Neri, MD, PhD; Noopur Raje, MD; Rakesh Popat, MD; Krina Patel, MD, MSc
CME Released: 12/30/2022
Valid for credit through: 12/30/2023

Start Activity

Credits Available

Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

You Are Eligible For
- Letter of Completion

Target Audience and Goal Statement

This activity is intended for hematology/oncology specialists and pathologists.

The goal of this activity is for the learner to be better able to understand the role of BCMA as a molecular target for the treatment of relapsed/refractory (R/R) multiple myeloma (MM), including clinical trial data on BCMA-targeted novel and emerging therapies (antibody-drug conjugates [ADCs], chimeric antigen receptor [CAR] T-cells, and bispecific antibodies/bispecific T-cell engagers) and key management considerations to optimize use.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Rationale for BCMA-directed therapies for the treatment of R/R MM
- Clinical trial data of BCMA-directed therapies for the treatment of R/R MM
Have greater competence related to
- Managing treatment-related adverse events (TRAEs) of BCMA-directed therapies for the treatment of R/R MM

Disclosures

Faculty

Paola Neri, MD, PhD

Associate Professor of Medicine
University of Calgary
Calgary, Alberta, Canada

Disclosures

Paola Neri, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Bristol Myers Squibb Company; Janssen Pharmaceuticals; Pfizer, Inc.; Sanofi

Noopur Raje, MD

Director
Center for Myeloma
Massachusetts General Hospital
Boston, Massachusetts, United States

Disclosures

Noopur Raje, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Amgen, Inc.; Bristol Myers Squibb Company; Caribou Bioscience; Immuneel Therapeutics; Janssen Pharmaceuticals; Pfizer, Inc.; Sanofi; Takeda Pharmaceuticals North America, Inc.
Research funding from: bluebird bio, Inc.

Rakesh Popat, MD

University College London Hospitals
NHS Foundation Trust
London, United Kingdom

Disclosures

Rakesh Popat, MD, has the following relevant financial relationships:
Consultant or advisor for: GlaxoSmithKline; Janssen
Speaker or member of speakers bureau for: AbbVie, Inc.; Bristol Myers Squibb Company; GlaxoSmithKline; Janssen Pharmaceuticals; Pfizer, Inc.
Research funding from: GlaxoSmithKline

Krina Patel, MD, MSc

Associate Professor
Center Medical Director
Department of Lymphoma/Myeloma
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas, United States

Disclosures

Krina Patel, MD, MSc, has the following relevant financial relationships:
Consultant or advisor for: Arcellx; Bristol Myers Squibb Company; Celgene Corporation; Cellectis; Janssen Pharmaceuticals; Karyopharm; Oncopeptides; Pfizer, Inc.
Contracted researcher for: Allogene Therapeutics; Bristol Myers Squibb Company; Celgene Corporation; Cellectis; Nektar Therapeutics; Precision Biosciences; Takeda Pharmaceuticals North America, Inc.

Editors

Sanneke Koekkoek

Medical Education Director, Medscape, LLC

Disclosures

Sanneke Koekkoek has no relevant financial relationships.

Eloise Ballard, PhD

Scientific Content Manager, Medscape, LLC

Disclosures

Eloise Ballard, PhD, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME

Managing Relapsed/Refractory Multiple Myeloma: The Ever-Expanding Role of B-Cell Maturation Antigen as a Molecular Target

Authors: Paola Neri, MD, PhD; Noopur Raje, MD; Rakesh Popat, MD; Krina Patel, MD, MScFaculty and Disclosures

CME Released: 12/30/2022

Valid for credit through: 12/30/2023

processing....

Select Any Chapter to Begin

Page 1 of 21

BCMA Basics - Pre-Assessment

Earn Credit CME Information Download Slides

Activity Transcript

PDF Downloads

Transcript Downloads

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Paola Neri, MD, PhD

Noopur Raje, MD

Rakesh Popat, MD

Krina Patel, MD, MSc

Editors

Sanneke Koekkoek

Eloise Ballard, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

CME

Managing Relapsed/Refractory Multiple Myeloma: The Ever-Expanding Role of B-Cell Maturation Antigen as a Molecular Target

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Paola Neri, MD, PhD

Noopur Raje, MD

Rakesh Popat, MD

Krina Patel, MD, MSc

Editors

Sanneke Koekkoek

Eloise Ballard, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Managing Relapsed/Refractory Multiple Myeloma: The Ever-Expanding Role of B-Cell Maturation Antigen as a Molecular Target

Select Any Chapter to Begin

PDF Downloads

Transcript Downloads